Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.80 |
| ▸ | FLT4 | P35916 | 6/20 | 0.66 |
| ▸ | KDR | P35968 | 6/20 | 0.66 |
| ▸ | KIT | P10721 | 4/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329807 | 1.00 | FLT3 (0.80) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15339392 | 0.89 | FLT3 (0.63) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15328167 | 0.89 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15328165 | 0.89 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15327966 | 0.87 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15327965 | 0.87 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15327960 | 0.85 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15327962 | 0.85 | FLT3 (1.00) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15328195 | 0.85 | AURKB (0.76) | FLT3AURKBFLT4KDRKIT | |
| SCHEMBL15328196 | 0.85 | AURKB (0.76) | FLT3AURKBFLT4KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | FLT3 1086/4885AURKB 100/4885FLT4 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.